Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Oral islatravir studied in new phase III trials as PrEP for HIV

March 5, 2021

New EFdA prodrugs synthesized at GlaxoSmithKline

March 3, 2021

Activation of CARD8 inflammasome triggers pyroptosis of HIV-1-infected cells

Feb. 24, 2021

Clinical study provides proof of principle for HIV vaccine candidate eOD-GT8 60mer

Feb. 5, 2021

California Institute of Technology, Rockefeller University describe anti-HIV vaccine antibodies

Feb. 4, 2021

CD40-targeting vaccine enhances T- and B-cell responses against HIV-1

Feb. 2, 2021

Merck & Co. presents preliminary safety and PK data for islatravir in HIV-1 pre-exposure prophylaxis

Jan. 28, 2021

NIAID reports phase IIb results on VRC-01 for HIV prevention

Jan. 27, 2021

FDA approves Cabenuva long-acting regimen for HIV-1 infection in adults

Jan. 22, 2021

A humanized mouse HIV latency model to test HIV cure strategies

Jan. 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...